Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2000003063

Enrollment

Unknown

Registered

2020-02-28

Start date

2020-03-09

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:traditional Chinese medicine

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Adult patients with confirmed 2019-nCoV

Exclusion criteria

Exclusion criteria: Severe liver and kidney damage, pulmonary tuberculosis, congenital heart disease, autoimmune disease, interstitial pneumonia, bacterial pneumonia, malignant tumor, history of psychiatric disease

Design outcomes

Primary

Measure	Time frame
blood RNA;	—

Countries

China

Contacts

Public ContactLi Caixia

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

li_caixia@zju.edu.cn+86 15268118258

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026